Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) will release its financial results for Q1 2022 on May 11, 2022, after market close. The call, hosted by CEO Ron Rocca and CFO Kamal Adawi, will begin at 4:30 PM ET. Interested parties can join via phone or webcast. Exagen focuses on autoimmune testing solutions, aiming to improve patient care through its AVISE® testing products, particularly for conditions like rheumatoid arthritis and lupus. For further details, visit their investor relations website.

Positive

• Exagen's ongoing commitment to enhancing autoimmune disease diagnostic solutions.
• Innovative AVISE® testing products aim to improve patient healthcare outcomes.

Negative

• None.

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (855) 238-9398 (U.S.) or (412) 317-5230 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Wednesday, May 18, 2022, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 10166625. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

CONTACTS:

Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514

FAQ

When will Exagen Inc. release its financial results for Q1 2022?

Exagen Inc. will release its financial results for Q1 2022 on May 11, 2022.

What time is Exagen's conference call scheduled for?

The conference call is scheduled for 4:30 PM ET on May 11, 2022.

How can I access Exagen's conference call?

You can access the call by dialing (855) 238-9398 in the U.S. or via the webcast link on Exagen's investor relations website.

What is Exagen's focus in the healthcare industry?

Exagen focuses on providing autoimmune testing solutions to improve diagnosis and treatment for patients with autoimmune diseases.

What technologies does Exagen use in its testing products?

Exagen utilizes proprietary technology called Cell-Bound Complement Activation Products (CB-CAPs) in its testing products.